AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31827656 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdecompression
Number of subjects: 100
Study 31827656 — intervention group
Group type: COMPARATOR
Intervention: Open wide laminectomy and posterior stabilization
Number of subjects: 100
Study 29273089 — intervention group
Group type: EXPERIMENTAL
Intervention: Famitinib
Number of subjects: 154
Study 29273089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 27262871 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone with or without hypothermia (exact dosage and duration not specified)
Number of subjects: 107
Study 27262871 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 107
Study 27262871 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 107
Study 24184091 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue Oasys
Number of subjects: 10
Study 24184091 — intervention group
Group type: EXPERIMENTAL
Intervention: Air Optix
Number of subjects: 10
Study 24184091 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofinity
Number of subjects: 10
Study 24184091 — intervention group
Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 10
Study 22341378 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching of the calf and hamstring muscles nightly for six weeks
Number of subjects: 80
Study 22341378 — intervention group
Group type: COMPARATOR
Intervention: No specific stretching exercises (Control)
Number of subjects: 80
Study 20708421 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/mL formulation of rhGH Nutropin AQ
Number of subjects: 0
Study 20708421 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg/mL formulation of rhGH Nutropin AQ
Number of subjects: 0
Study 20708421 — intervention group
Group type: COMPARATOR
Intervention: 10 mg/mL formulation of rhGH Nutropin AQ
Number of subjects: 0
Study 17032732 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist Cetrorelix with recombinant FSH (rFSH) in group A (n = 52)
Number of subjects: 104
Study 17032732 — intervention group
Group type: COMPARATOR
Intervention: rFSH alone in group B (n = 52)
Number of subjects: 104
Study 17032732 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist Cetrorelix with rFSH in group A
Number of subjects: 104
Study 17032732 — intervention group
Group type: COMPARATOR
Intervention: rFSH alone in group B
Number of subjects: 104
Study 16264123 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic hip examination
Number of subjects: 629
Study 16264123 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment alone
Number of subjects: 629
Study 12030546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg 17beta-estradiol (E2)
Number of subjects: 166
Study 12030546 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg 17beta-estradiol (E2)
Number of subjects: 166
Study 12030546 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg 17beta-estradiol (E2)
Number of subjects: 166
Study 12030546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 9477049 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 20
Study 9477049 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 20
Study 7554335 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior turbinectomy
Number of subjects: 214
Study 7554335 — intervention group
Group type: COMPARATOR
Intervention: Radical turbinectomy
Number of subjects: 214
Study 1847582 — intervention group
Group type: EXPERIMENTAL
Intervention: Provera 20 mg
Number of subjects: 81
Study 1847582 — intervention group
Group type: EXPERIMENTAL
Intervention: Premarin 0.6 mg
Number of subjects: 81
Study 1847582 — intervention group
Group type: EXPERIMENTAL
Intervention: Premarin 0.3 mg plus Provera 10 mg
Number of subjects: 81
Study 1847582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 6841821 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure-tone signals with interaural phase shifts ranging between 90 degrees and 360 degrees, with rise/decay time varied from 5 to 200 ms.
Number of subjects: 0
Study 30979941 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 0
Study 30979941 — intervention group
Group type: COMPARATOR
Intervention: Wakefulness
Number of subjects: 0
Study 30414609 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.08% alone
Number of subjects: 59
Study 30414609 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25% plus ketorolac tromethamine 0.08%
Number of subjects: 59
Study 30414609 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25% alone
Number of subjects: 59
Study 30414609 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 59
Study 25870994 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg once daily)
Number of subjects: 300
Study 25870994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 23175179 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (3 sets, 8 RM, 9 exercises)
Number of subjects: 16
Study 23175179 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 23175179 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 16
Study 22054336 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored package of housing improvements providing adequate ventilation and temperature
Number of subjects: 192
Study 19420915 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 40
Study 19420915 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 40
Study 19420915 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 16952918 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA (lidocaine 2 mg kg(‐1) followed by 3 mg kg(‐1) h(‐1) epidurally)
Number of subjects: 60
Study 16952918 — intervention group
Group type: EXPERIMENTAL
Intervention: IV (lidocaine i.v. with normal saline epidurally)
Number of subjects: 60
Study 16952918 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline via both routes)
Number of subjects: 60
Study 15298876 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA‐ProSeal
Number of subjects: 60
Study 15298876 — intervention group
Group type: COMPARATOR
Intervention: LMA‐Classic
Number of subjects: 60
Study 11189688 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies tailored to individual catchment areas at screening centers
Number of subjects: 150000
Study 11189688 — intervention group
Group type: EXPERIMENTAL
Intervention: National level recruitment efforts initiated by the NCI
Number of subjects: 150000
Study 8828533 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 73
Study 8828533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 8828533 — intervention group
Group type: COMPARATOR
Intervention: Oral budesonide
Number of subjects: 73
Study 8828533 — intervention group
Group type: EXPERIMENTAL
Intervention: DVPF
Number of subjects: 73
Study 8828533 — intervention group
Group type: EXPERIMENTAL
Intervention: LPF
Number of subjects: 73
Study 1595097 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracranial-intracranial bypass surgery (group A)
Number of subjects: 104
Study 1595097 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 104
Study 6731693 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential pneumatic leg compression at pressures of 90 to 100 mm Hg
Number of subjects: 25
Study 6731693 — intervention group
Group type: COMPARATOR
Intervention: Sequential pneumatic leg compression at pressures of 35 mm Hg
Number of subjects: 25
Study 6731693 — intervention group
Group type: COMPARATOR
Intervention: Heparin 5,000 units three times per day
Number of subjects: 25
Study 6731693 — intervention group
Group type: COMPARATOR
Intervention: Sequential pneumatic leg compression at pressures of 35 to 55 mm Hg
Number of subjects: 25
Study 30564869 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/day)
Number of subjects: 20
Study 30564869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30019477 — intervention group
Group type: EXPERIMENTAL
Intervention: Transformational leadership of nurse managers
Number of subjects: 131
Study 30019477 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural empowerment of nurses
Number of subjects: 131
Study 30019477 — intervention group
Group type: EXPERIMENTAL
Intervention: Transformational leadership of managers
Number of subjects: 131
Study 26660709 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioural parent training (CBPT)
Number of subjects: 0
Study 26660709 — intervention group
Group type: COMPARATOR
Intervention: Group cognitive-behavioural parent training (CBPT)
Number of subjects: 0
Study 26660709 — intervention group
Group type: COMPARATOR
Intervention: Medication (not specified if it was part of the intervention)
Number of subjects: 0
Study 25232955 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary outpatient rehabilitation (MDR)
Number of subjects: 48
Study 25232955 — intervention group
Group type: COMPARATOR
Intervention: MS-nurse consultation
Number of subjects: 48
Study 22615318 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin treatment
Number of subjects: 293
Study 22615318 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline treatment
Number of subjects: 293
Study 22615318 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole treatment
Number of subjects: 293
Study 19854001 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid attentional engagement toward social stress words
Number of subjects: 25
Study 19854001 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow attentional engagement toward social stress words
Number of subjects: 25
Study 19854001 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast engagers of social stress information
Number of subjects: 25
Study 19854001 — intervention group
Group type: COMPARATOR
Intervention: Groups (fast and slow engagers)
Number of subjects: 25
Study 17662790 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined general and high thoracic epidural anesthesia (GA+TEA)
Number of subjects: 132
Study 17662790 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 132
Study 16247294 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic testing
Number of subjects: 2165
Study 16247294 — intervention group
Group type: COMPARATOR
Intervention: Phenotypic testing
Number of subjects: 2165
Study 12406050 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus exercise (brisk walking intervention)
Number of subjects: 52
Study 12406050 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 52
Study 10445378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsapirone (0.3 mg/kg body weight)
Number of subjects: 30
Study 10445378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7559245 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate (HR) measured at various temperatures (22°C, 28°C, 32°C, 35°C) during exercise and rest periods.
Number of subjects: 20
Study 7559245 — intervention group
Group type: EXPERIMENTAL
Intervention: HR calculated at 22°C (HRcalc22) using individual regression lines.
Number of subjects: 20
Study 7559245 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction of HR for climate influence during rest and exercise.
Number of subjects: 20
Study 2121079 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic air (30% O2)
Number of subjects: 36
Study 2121079 — intervention group
Group type: COMPARATOR
Intervention: Normoxic air (21% O2)
Number of subjects: 36
Study 2121079 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental O2 (30% O2)
Number of subjects: 36
Study 341905 — intervention group
Group type: EXPERIMENTAL
Intervention: Halopredone acetate cream (0.01%)
Number of subjects: 30
Study 341905 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone valerate (0.1%)
Number of subjects: 30
Study 31811692 — intervention group
Group type: EXPERIMENTAL
Intervention: Language intervention
Number of subjects: 0
Study 30953556 — intervention group
Group type: EXPERIMENTAL
Intervention: iBobbly app (self-help app based on acceptance and commitment therapy)
Number of subjects: 0
Study 30953556 — intervention group
Group type: COMPARATOR
Intervention: wait-list control condition
Number of subjects: 0
Study 27807198 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxycycline
Number of subjects: 62
Study 27807198 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 24807396 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil combined with fentanyl (FA)
Number of subjects: 40
Study 24807396 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl alone (F)
Number of subjects: 40
Study 23630367 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection plus exercise (n = 115)
Number of subjects: 232
Study 23630367 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone (n = 117)
Number of subjects: 232
Study 22146167 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-abdominal pressure at 16 mm Hg (group 3)
Number of subjects: 60
Study 22146167 — intervention group
Group type: COMPARATOR
Intervention: Intra-abdominal pressure at 10 mm Hg (group 1)
Number of subjects: 60
Study 22146167 — intervention group
Group type: COMPARATOR
Intervention: Intra-abdominal pressure at 13 mm Hg (group 2)
Number of subjects: 60
Study 19250364 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oxytocin group
Number of subjects: 630
Study 19250364 — intervention group
Group type: COMPARATOR
Intervention: Expectant group (delayed oxytocin)
Number of subjects: 630
Study 16479024 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (0.25 mg/day)
Number of subjects: 67
Study 16479024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 14757613 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aspirin use (> or =2 standard aspirin tablets/wk)
Number of subjects: 27077
Study 14757613 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use of 0.5 to 1.5 standard tablets per week
Number of subjects: 27077
Study 14757613 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use of 2 to 5 tablets per week
Number of subjects: 27077
Study 14757613 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use of 6 to 14 tablets per week
Number of subjects: 27077
Study 14757613 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use of more than 14 tablets per week
Number of subjects: 27077
Study 14757613 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular short-term aspirin use (< or =5 years)
Number of subjects: 27077
Study 14757613 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular long-term aspirin use (>5 years)
Number of subjects: 27077
Study 14757613 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing duration of aspirin use
Number of subjects: 27077
Study 11511404 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 66
Study 11511404 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 150 mg
Number of subjects: 66
Study 11511404 — intervention group
Group type: COMPARATOR
Intervention: Control group (Fluoxetine)
Number of subjects: 66
Study 9699704 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (N=31)
Number of subjects: 61
Study 9699704 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline (N=30)
Number of subjects: 61
Study 7874151 — intervention group
Group type: EXPERIMENTAL
Intervention: Strenuous bout of resistive exercise (REx)
Number of subjects: 0
Study 7874151 — intervention group
Group type: COMPARATOR
Intervention: Stationary cycling (AEx) at 50% peak VO2
Number of subjects: 0
Study 7874151 — intervention group
Group type: COMPARATOR
Intervention: Control condition (C) of quiet sitting
Number of subjects: 0
Study 3074627 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymic hormone
Number of subjects: 41
Study 3074627 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentapeptide treatment
Number of subjects: 41
Study 3074627 — intervention group
Group type: COMPARATOR
Intervention: Thymic therapy
Number of subjects: 41
Study 31886683 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting in 2 Worlds (P2W)
Number of subjects: 575
Study 31886683 — intervention group
Group type: COMPARATOR
Intervention: Healthy Families in 2 Worlds (HF2W)
Number of subjects: 575
Study 29016984 — intervention group
Group type: EXPERIMENTAL
Intervention: Hidden conditioning
Number of subjects: 90
Study 29016984 — intervention group
Group type: EXPERIMENTAL
Intervention: Open conditioning
Number of subjects: 90
Study 29016984 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 27697429 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-week rehabilitation program (long duration)
Number of subjects: 66
Study 27697429 — intervention group
Group type: COMPARATOR
Intervention: 7-week rehabilitation program (short duration)
Number of subjects: 66
Study 26149602 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX-DEBIRI
Number of subjects: 70
Study 26149602 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX/bevacizumab
Number of subjects: 70
Study 23758719 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual risk‐reduction intervention
Number of subjects: 26
Study 20349684 — intervention group
Group type: EXPERIMENTAL
Intervention: adapalene 0.1%-benzoyl peroxide 2.5% (A/BPO) fixed-dose combination gel with doxycycline hyclate 100 mg
Number of subjects: 459
Study 20349684 — intervention group
Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 459
Study 18490245 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Gy + zoledronic acid (4 mg iv, in 15‐min infusions)
Number of subjects: 139
Study 18490245 — intervention group
Group type: COMPARATOR
Intervention: 6 Gy + zoledronic acid (4 mg iv, in 15‐min infusions)
Number of subjects: 139
Study 15941414 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus Artesunate (AQ/AS)
Number of subjects: 240
Study 15941414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-Pyrimethamine (SP)
Number of subjects: 240
Study 15941414 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 240
Study 15941414 — intervention group
Group type: COMPARATOR
Intervention: Amodiaquine (AQ)
Number of subjects: 240
Study 12902587 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Interviewer and Computerised Questionnaire Method (TICQM)
Number of subjects: 1162
Study 12902587 — intervention group
Group type: COMPARATOR
Intervention: Telephone Interviewer Method (TIM)
Number of subjects: 1162
Study 12902587 — intervention group
Group type: EXPERIMENTAL
Intervention: TICQM (for sexually active females)
Number of subjects: 1162
Study 12902587 — intervention group
Group type: EXPERIMENTAL
Intervention: TICQM (for sexually active males)
Number of subjects: 1162
Study 10497712 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (22%)
Number of subjects: 10
Study 8604620 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator (TPA)
Number of subjects: 1473
Study 8604620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1473
Study 8604620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin titrated to an activated partial thromboplastin time (aPTT) of 1.5 to 2.0 times control for 72 to 96 hours
Number of subjects: 1473
Study 8604620 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal anticoagulation (all aPTTs >60 seconds, all heparin levels>0.2 U/ml)
Number of subjects: 1473
Study 8604620 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive (high-intensity) anticoagulation with heparin to achieve aPTTs >2.0 times control
Number of subjects: 1473
Study 8604620 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine aPTT monitoring
Number of subjects: 1473
Study 8604620 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy with heparin and aspirin
Number of subjects: 1473
Study 1940267 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (20 mg intravenous)
Number of subjects: 19
Study 1940267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7004176 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 22
Study 7004176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31735645 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA, 20 min) 5 times a week during the first month post stroke
Number of subjects: 50
Study 31735645 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 50
Study 30975961 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced platelet-rich fibrin (A-PRF)
Number of subjects: 27
Study 30975961 — intervention group
Group type: COMPARATOR
Intervention: Leukocyte- and platelet-rich fibrin (L-PRF)
Number of subjects: 27
Study 28451764 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance device (Group A)
Number of subjects: 96
Study 28451764 — intervention group
Group type: COMPARATOR
Intervention: James formula (Group B)
Number of subjects: 96
Study 25817849 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone, 1 mg/kg, intravenous at induction of anesthesia
Number of subjects: 20
Study 25817849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24308746 — intervention group
Group type: EXPERIMENTAL
Intervention: Single one-off education/exercise class for low risk patients
Number of subjects: 47
Study 24308746 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 week group exercise/education intervention for medium risk patients
Number of subjects: 47
Study 24308746 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 week group cognitive behavioural approach for high risk patients
Number of subjects: 47
Study 24308746 — intervention group
Group type: COMPARATOR
Intervention: Generic group intervention for all patients in historical control group
Number of subjects: 47
Study 24308746 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (low, medium, high risk)
Number of subjects: 47
Study 21318581 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal haemorrhoidal dearterialisation (THD)
Number of subjects: 52